TEN WAYS TO PROMOTE TEN WAYS TO PROMOTE RELATIONSHIPS WITH PATIENTS RELATIONSHIPS WITH PATIENTS 1. 1. Greet patients by name, tell them Greet patients by name, tell them your name and role in their care your name and role in their care 2. 2. Smile Smile 3. 3. Sit down when talking to patients Sit down when talking to patients 4. 4. Listen Listen 5. 5. Be wholly present with Be wholly present with interacting with patients and interacting with patients and avoid unnecessary interruptions avoid unnecessary interruptions Wright, et al; Am J Med 2005
TEN WAYS TO PROMOTE RELATIONSHIPS WITH PATIENTS. Greet patients by name, tell them your name and role in their care Smile Sit down when talking to patients Listen Be wholly present with interacting with patients and avoid unnecessary interruptions. Wright, et al; Am J Med 2005. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
TEN WAYS TO PROMOTE TEN WAYS TO PROMOTE RELATIONSHIPS WITH PATIENTSRELATIONSHIPS WITH PATIENTS
1.1. Greet patients by name, tell them your Greet patients by name, tell them your name and role in their carename and role in their care
2.2. SmileSmile
3.3. Sit down when talking to patientsSit down when talking to patients
4.4. ListenListen
5.5. Be wholly present with interacting with Be wholly present with interacting with patients and avoid unnecessary patients and avoid unnecessary interruptionsinterruptions
Wright, et al; Am J Med 2005
TEN WAYS TO PROMOTE TEN WAYS TO PROMOTE RELATIONSHIPS WITH PATIENTSRELATIONSHIPS WITH PATIENTS
6.6. Learn who your patients are and consider sharing Learn who your patients are and consider sharing something about yourself with themsomething about yourself with them
7.7. Show the utmost respect for all patientsShow the utmost respect for all patients
8.8. Be humanistic, compassionate, and caringBe humanistic, compassionate, and caring
9.9. Even if it is a struggle to think positively of a patient, Even if it is a struggle to think positively of a patient, always speak of them in a positive way; this will always speak of them in a positive way; this will influence your thinking positivelyinfluence your thinking positively
10.10.If you are feeling negative emotions towards a If you are feeling negative emotions towards a patient, try to understand why you are feeling this patient, try to understand why you are feeling this wayway
Wright, et al; Am J Med 2005
The most common metabolic liver The most common metabolic liver disease in children is:disease in children is:
• A) Alpha-1 Antitrypsin deficiencyA) Alpha-1 Antitrypsin deficiency• B) HemochromatosisB) Hemochromatosis• C) Wilson’s DiseaseC) Wilson’s Disease• D) Cystic FibrosisD) Cystic Fibrosis• E) Familial Intrahepatic CholestasisE) Familial Intrahepatic Cholestasis
The most common metabolic liver The most common metabolic liver disease in children is:disease in children is:
• A) Alpha-1 Antitrypsin deficiencyA) Alpha-1 Antitrypsin deficiency• B) HemochromatosisB) Hemochromatosis• C) Wilson’s DiseaseC) Wilson’s Disease• D) Cystic FibrosisD) Cystic Fibrosis• E) Familial Intrahepatic CholestasisE) Familial Intrahepatic Cholestasis
The least common metabolic liver The least common metabolic liver disease in children is:disease in children is:
• A) Alpha-1 Antitrypsin deficiencyA) Alpha-1 Antitrypsin deficiency• B) HemochromatosisB) Hemochromatosis• C) Wilson’s DiseaseC) Wilson’s Disease• D) Cystic FibrosisD) Cystic Fibrosis• E) Familial Intrahepatic CholestasisE) Familial Intrahepatic Cholestasis
The least common metabolic liver The least common metabolic liver disease in children is:disease in children is:
• A) Alpha-1 Antitrypsin deficiencyA) Alpha-1 Antitrypsin deficiency• B) HemochromatosisB) Hemochromatosis• C) Wilson’s DiseaseC) Wilson’s Disease• D) Cystic FibrosisD) Cystic Fibrosis• E) Familial Intrahepatic CholestasisE) Familial Intrahepatic Cholestasis
AGA Clinical Teaching Project: Unit 8
Which of the following is not seen in HH?Which of the following is not seen in HH?
• A) HepatomegalyA) Hepatomegaly• B) Hypogonadotropic hypogonadismB) Hypogonadotropic hypogonadism• C) HypothyroidismC) Hypothyroidism• D) Heart FailureD) Heart Failure• E) Destructive arthritisE) Destructive arthritis• F) ErythrocytosisF) Erythrocytosis
Which of the following is not seen in HH?Which of the following is not seen in HH?
• A) HepatomegalyA) Hepatomegaly• B) Hypogonadotropic hypogonadismB) Hypogonadotropic hypogonadism• C) HypothyroidismC) Hypothyroidism• D) Heart FailureD) Heart Failure• E) Destructive arthritisE) Destructive arthritis• F) ErythrocytosisF) Erythrocytosis
HEREDITARY HEMOCHROMATOSISHEREDITARY HEMOCHROMATOSISDefinition and InheritanceDefinition and Inheritance
• Increased intestinal absorption of ironIncreased intestinal absorption of iron• Deposition in multiple parenchymal Deposition in multiple parenchymal
organsorgans• Autosomal recessiveAutosomal recessive• Common in CaucasiansCommon in Caucasians
–homozygote frequency - 0.5%homozygote frequency - 0.5%–heterozygote frequency - 10%heterozygote frequency - 10%
HFE HFE GENE GENE
• Discovered in 1996 Discovered in 1996
• Two mutations initially described Two mutations initially described (C282Y and H63D)(C282Y and H63D)
• 60-100% of patients with HH are 60-100% of patients with HH are C282Y/C282YC282Y/C282Y
• 5-10% of patients with clinically 5-10% of patients with clinically significant iron overload don’t have significant iron overload don’t have HFEHFE mutations mutations
Adams, et al; NEJM 2005
Adams, et al; NEJM 2005
HFEHFE AND IRON OVERLOAD AND IRON OVERLOADSupporting evidenceSupporting evidence
• Wild type and H63D protein bind to Wild type and H63D protein bind to -2 -2 microglobulin (microglobulin (-2 M)-2 M)– expressed on the cell surface expressed on the cell surface – facilitates iron uptakefacilitates iron uptake
• C282Y protein does not bind to C282Y protein does not bind to -2 M and is not -2 M and is not expressed on the cell surfaceexpressed on the cell surface
• HFEHFE knock out mice and knock out mice and -2 M knockout mice -2 M knockout mice develop HHdevelop HH
• We still don’t know how the mutated We still don’t know how the mutated HFE HFE protein protein causes iron overloadcauses iron overload
There are 4 types of iron overload- can There are 4 types of iron overload- can you rank them in terms of severity?you rank them in terms of severity?
• Type 1: HFE related HH (adult)Type 1: HFE related HH (adult)• Type 2A: Hemojuvelin related juvenile HCType 2A: Hemojuvelin related juvenile HC• Type 2B: Hepcidin related juvenile HCType 2B: Hepcidin related juvenile HC• Type 3: Transferrin receptor 2 HC (adult)Type 3: Transferrin receptor 2 HC (adult)• Type 4: Ferroportin related iron overload (note: this is the Type 4: Ferroportin related iron overload (note: this is the
only AD one)only AD one)
Pietrangelo, et al; NEJM 2004
HEPCIDINHEPCIDIN
• 25 aa peptide synthesized in hepatocytes25 aa peptide synthesized in hepatocytes
• HAMP HAMP gene on chromosome 19qgene on chromosome 19q
• Stimulated by inflammation and iron Stimulated by inflammation and iron excessexcess
• Down-regulates ferroportin-mediated Down-regulates ferroportin-mediated release from enterocytes, placenta, and release from enterocytes, placenta, and macrophages macrophages
• Levels increase 100X in anemia of of Levels increase 100X in anemia of of chronic disease chronic disease
Park et al. J Biol Chem 2001.
HEPCIDIN-2HEPCIDIN-2
• Hepcidin mRNA induced by dietary and Hepcidin mRNA induced by dietary and parenteral iron overloadparenteral iron overload
• Anemia and hypoxia suppress hepcidin Anemia and hypoxia suppress hepcidin
• Hepcidin KO mice develop iron overloadHepcidin KO mice develop iron overload
• Over expression leads to iron deficiencyOver expression leads to iron deficiency
• HFE HFE KO mice and humans with HH have KO mice and humans with HH have inappropriately low hepcidin levelsinappropriately low hepcidin levels
Ahmad Blood Cells Mol Dis. 2002; Bridle Lancet 2003
Papanikolaou Nature Genetics 2004
The earliest sign of HC is:The earliest sign of HC is:
• A) elevated ferritinA) elevated ferritin• B) elevated transferrin saturationB) elevated transferrin saturation• C) Impaired OGTTC) Impaired OGTT• D) 1D) 1stst and 2 and 2ndnd MCP joint destruction MCP joint destruction
The earliest sign of HC is:The earliest sign of HC is:
• A) elevated ferritinA) elevated ferritin• B) elevated transferrin saturationB) elevated transferrin saturation• C) Impaired OGTTC) Impaired OGTT• D) 1D) 1stst and 2 and 2ndnd MCP joint destruction MCP joint destruction
30 yo asymptomatic female is referred for elevated 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); g/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 TS% = 80% (normal 14-50%); ferritin = 80 g/L g/L (normal 20-200). PMH and FMH are unremarkable. (normal 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does She consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat not use iron supplements. Exam is normal. Repeat TS is 74%. TS is 74%. What would you recommend?What would you recommend?
4. MRI of the liver to look for iron deposition4. MRI of the liver to look for iron deposition
5. 5. HFE HFE gene test and phlebotomygene test and phlebotomy
30 yo asymptomatic female is referred for elevated 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); g/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 TS% = 80% (normal 14-50%); ferritin = 80 g/L g/L (normal 20-200). PMH and FMH are unremarkable. (normal 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does She consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat not use iron supplements. Exam is normal. Repeat TS is 74%. TS is 74%. What would you recommend?What would you recommend?
4. MRI of the liver to look for iron deposition4. MRI of the liver to look for iron deposition
5. 5. HFE HFE gene test and phlebotomygene test and phlebotomy
Recheck in 1 year
Fasting, morning TS % > 45% StopNo
Repeat TS % and serum ferritin elevated
Secondary iron overload?
HFE gene testing Treat and recheck
Yes
Yes
No
No
Yes
Clinical Suspicion of HH
WHO SHOULD BE TESTED FOR HH?WHO SHOULD BE TESTED FOR HH?
• Adult 1st degree relatives of a proband (Adult 1st degree relatives of a proband (HFEHFE))• Patients with persistent liver test abnormalities Patients with persistent liver test abnormalities
or chronic liver disease (TS%)or chronic liver disease (TS%)• Patients with one or more symptoms/signs Patients with one or more symptoms/signs
suggestive of HH (TS%)suggestive of HH (TS%)– diabetesdiabetes– heart failure or cardiac arrhythmiasheart failure or cardiac arrhythmias– young patients with “DJD”young patients with “DJD”
• Patients with porphyria cutanea tarda (Patients with porphyria cutanea tarda (HFEHFE))
HEREDITARY HEMOCHROMATOSISHEREDITARY HEMOCHROMATOSISClinical FeaturesClinical Features
• Iron accumulation is slow (1-2 mg excess iron per Iron accumulation is slow (1-2 mg excess iron per day)day)
• Clinical manifestations often do not occur until 5th Clinical manifestations often do not occur until 5th decadedecade
• Clinical manifestations in females may be mild Clinical manifestations in females may be mild and/or delayedand/or delayed
• Alcohol, hepatitis C, and other ill-defined Alcohol, hepatitis C, and other ill-defined environmental and genetic factors may influence environmental and genetic factors may influence disease progressiondisease progression
A 30 yo asymptomatic female is referred for elevated A 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); g/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 TS% = 80% (normal 14-50%); ferritin = 80 g/L g/L (normal 20-200). PMH and FMH are unremarkable. (normal 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does She consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat not use iron supplements. Exam is normal. Repeat TS is 74%. She is homozygous for C282Y. She asks TS is 74%. She is homozygous for C282Y. She asks about treatment. about treatment. What would you recommend?What would you recommend?
1. Phlebotomy1. Phlebotomy
2. Deferoxamine2. Deferoxamine
3. No treatment but follow iron tests3. No treatment but follow iron tests
4. A “low iron” diet4. A “low iron” diet
A 30 yo asymptomatic female is referred for elevated A 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); g/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 TS% = 80% (normal 14-50%); ferritin = 80 g/L g/L (normal 20-200). PMH and FMH are unremarkable. (normal 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does She consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat not use iron supplements. Exam is normal. Repeat TS is 74%. She is homozygous for C282Y. She asks TS is 74%. She is homozygous for C282Y. She asks about treatment. about treatment. What would you recommend?What would you recommend?
1. Phlebotomy1. Phlebotomy
2. Deferoxamine2. Deferoxamine
3. No treatment but follow iron tests3. No treatment but follow iron tests
4. A “low iron” diet4. A “low iron” diet
POPULATION SCREENING STUDIESPOPULATION SCREENING STUDIESGenotype and PhenotypeGenotype and Phenotype
A 30 yo asymptomatic female is referred for elevated A 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); TSg/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 % = 80% (normal 14-50%); ferritin = 80 g/L (normal g/L (normal 20-200). PMH and FMH are unremarkable. She 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does not consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat TS is use iron supplements. Exam is normal. Repeat TS is 74%. She is homozygous for C282Y. She inquires 74%. She is homozygous for C282Y. She inquires about screening her brothers and daughter. about screening her brothers and daughter. What What would you suggest?would you suggest?
1. No screening necessary1. No screening necessary
2. 2. HFE HFE gene test for bothgene test for both
3. Transferrin saturation for both3. Transferrin saturation for both
4. 4. HFE HFE gene test for her brothers gene test for her brothers
A 30 yo asymptomatic female is referred for elevated A 30 yo asymptomatic female is referred for elevated serum iron studies obtained as part of her routine serum iron studies obtained as part of her routine health evaluation. Iron = 180 health evaluation. Iron = 180 g/dl (normal 35-145); TSg/dl (normal 35-145); TS% = 80% (normal 14-50%); ferritin = 80 % = 80% (normal 14-50%); ferritin = 80 g/L (normal g/L (normal 20-200). PMH and FMH are unremarkable. She 20-200). PMH and FMH are unremarkable. She consumes 3 glasses of wine per week and does not consumes 3 glasses of wine per week and does not use iron supplements. Exam is normal. Repeat TS is use iron supplements. Exam is normal. Repeat TS is 74%. She is homozygous for C282Y. She inquires 74%. She is homozygous for C282Y. She inquires about screening her brothers and daughter. about screening her brothers and daughter. What What would you suggest?would you suggest?
1. No screening necessary1. No screening necessary
2. 2. HFE HFE gene test for bothgene test for both
3. Transferrin saturation for both3. Transferrin saturation for both
4. 4. HFE HFE gene test for her brothers gene test for her brothers
HFE Gene Test(adults only)
Family History of C282Y Homozygous HH
C282Y homozygote
C282Y Heterozygote
No C282Y Mutation
No further evaluation
Serum TS % and Ferritin
Increased
Normal
Follow and consider liver biopsy or trial of quantitative phlebotomy if ferritin is >500 g/L
Serum TS % and Ferritin
Liver biopsy and
phlebotomy
Ferritin elevated but < 1000 g/L and normal
AST
Ferritin > 1000 g/L and/or
elevated AST
Phlebotomy
Ferritin normal
Repeat ferritinannually
One of her brothers is homozygous for C282Y. One of her brothers is homozygous for C282Y. His serum iron is 220 His serum iron is 220 g/dl, TS=88% and g/dl, TS=88% and ferritin 575 ferritin 575 g/L. His liver tests are normal. He g/L. His liver tests are normal. He is healthy and asymptomatic. He consumes 1 is healthy and asymptomatic. He consumes 1 alcoholic beverage per day. alcoholic beverage per day. What would you What would you recommend?recommend?
1. Liver biopsy followed by phlebotomy1. Liver biopsy followed by phlebotomy
2. Phlebotomy2. Phlebotomy
3. MRI to assess hepatic iron stores3. MRI to assess hepatic iron stores
4. Stop alcohol and repeat iron tests in 3 mos4. Stop alcohol and repeat iron tests in 3 mos
5. Observation 5. Observation
One of her brothers is homozygous for C282Y. One of her brothers is homozygous for C282Y. His serum iron is 220 His serum iron is 220 g/dl, TS=88% and g/dl, TS=88% and ferritin 575 ferritin 575 g/L. His liver tests are normal. He g/L. His liver tests are normal. He is healthy and asymptomatic. He consumes 1 is healthy and asymptomatic. He consumes 1 alcoholic beverage per day. alcoholic beverage per day. What would you What would you recommend?recommend?
1. Liver biopsy followed by phlebotomy1. Liver biopsy followed by phlebotomy
2. Phlebotomy2. Phlebotomy
3. MRI to assess hepatic iron stores3. MRI to assess hepatic iron stores
4. Stop alcohol and repeat iron tests in 3 mos4. Stop alcohol and repeat iron tests in 3 mos
5. Observation 5. Observation
LIVER BIOPSY IN LIVER BIOPSY IN HEMOCHROMATOSISHEMOCHROMATOSIS
• RationaleRationale
- confirm diagnosisconfirm diagnosis
- exclude cirrhosisexclude cirrhosis
• Liver biopsy not needed to confirm diagnosis of Liver biopsy not needed to confirm diagnosis of HH in patients homozygous for C282Y with an HH in patients homozygous for C282Y with an elevated transferrin saturation and ferritin.elevated transferrin saturation and ferritin.
• Cirrhosis rare in C282Y homozygotes with Cirrhosis rare in C282Y homozygotes with ferritin < 1000 ferritin < 1000 g/L and normal g/L and normal aminotransferases.aminotransferases.
CP1022478-3
In a patient with HH and cirrhosis, the In a patient with HH and cirrhosis, the risk of HCC isrisk of HCC is
• A) Higher than that of viral hepatitisA) Higher than that of viral hepatitis• B) Lower than viral but higher than NASHB) Lower than viral but higher than NASH• C) Lower than NASH, but higher than cholestatic diseasesC) Lower than NASH, but higher than cholestatic diseases• D) very lowD) very low
In a patient with HH and cirrhosis, the In a patient with HH and cirrhosis, the risk of HCC isrisk of HCC is
• A) Higher than that of viral hepatitisA) Higher than that of viral hepatitis• B) Lower than viral but higher than NASHB) Lower than viral but higher than NASH• C) Lower than NASH, but higher than cholestatic diseasesC) Lower than NASH, but higher than cholestatic diseases• D) very lowD) very low
HEMOCHROMATOSIS AND CIRRHOSISHEMOCHROMATOSIS AND CIRRHOSIS
• Major predictor of survivalMajor predictor of survival
• Complications of ESLD uncommonComplications of ESLD uncommon
• Death usually due to liver cancer Death usually due to liver cancer
–30% with HH cirrhosis develop HCC30% with HH cirrhosis develop HCC
–200X increased risk 200X increased risk
–Risk persists despite iron depletionRisk persists despite iron depletion
–HCC rare in the absence of cirrhosisHCC rare in the absence of cirrhosis
Liver biopsy histology and HIC Liver biopsy histology and HIC consistent with HH?consistent with HH?
Liver biopsy histology and HIC Liver biopsy histology and HIC consistent with HH?consistent with HH?
CP1134735-1
Clinical suspicion of HHClinical suspicion of HHClinical suspicion of HHClinical suspicion of HH
Blue=reversible, yellow=usually not reversible; Modified from AGA clinical teaching projectBlue=reversible, yellow=usually not reversible; Modified from AGA clinical teaching project
• AvoidAvoid– ETOHETOH– iron and vitamin C supplementsiron and vitamin C supplements– raw shellfishraw shellfish
• A “low iron diet” is not necessaryA “low iron diet” is not necessary• Vaccinate against hepatitis A and BVaccinate against hepatitis A and B
A 35 yo female is found to have an elevated serum ferritin. A 35 yo female is found to have an elevated serum ferritin. Serum iron 120 Serum iron 120 g/dl, TS%=35%, ferritin=814 g/dl, TS%=35%, ferritin=814 g/L. g/L.
PMH: Hepatitis CPMH: Hepatitis C
Meds: MVI with iron (for 1 year) Meds: MVI with iron (for 1 year)
PE: NormalPE: Normal
Labs: Hgb= 11 g/dl. AST=95, ALT= 134, the rest of her liver Labs: Hgb= 11 g/dl. AST=95, ALT= 134, the rest of her liver tests are normal.tests are normal.
What is the most likely explanation for her abnormal serum iron What is the most likely explanation for her abnormal serum iron studies?studies?
4. Excess iron supplementation4. Excess iron supplementation
A 35 yo female is found to have an elevated serum ferritin. A 35 yo female is found to have an elevated serum ferritin. Serum iron 120 Serum iron 120 g/dl, TS%=35%, ferritin=814 g/dl, TS%=35%, ferritin=814 g/L. g/L.
PMH: Hepatitis CPMH: Hepatitis C
Meds: MVI with iron (for 1 year) Meds: MVI with iron (for 1 year)
PE: NormalPE: Normal
Labs: Hgb= 11 g/dl. AST=95, ALT= 134, the rest of her liver Labs: Hgb= 11 g/dl. AST=95, ALT= 134, the rest of her liver tests are normal.tests are normal.
What is the most likely explanation for her abnormal serum iron What is the most likely explanation for her abnormal serum iron studies?studies?
• Elevated serum ferritin is the first clinical Elevated serum ferritin is the first clinical manifestation (usually in the first decade)manifestation (usually in the first decade)
• TS% elevated as iron overload more TS% elevated as iron overload more severesevere
• Clinical manifestations tend to be mildClinical manifestations tend to be mild• Hepatic fibrosis absent or mild in mostHepatic fibrosis absent or mild in most• Mild anemia commonMild anemia common
55 yo male with elevated serum iron studies. He has 55 yo male with elevated serum iron studies. He has diabetes, arthritis, impotence and atrial fibrillation. diabetes, arthritis, impotence and atrial fibrillation. He consumes 2-3 beers per week.He consumes 2-3 beers per week.
4. MRI to look for hepatic iron deposition 4. MRI to look for hepatic iron deposition
55 yo male with elevated serum iron studies. He has 55 yo male with elevated serum iron studies. He has diabetes, arthritis, impotence and atrial fibrillation. diabetes, arthritis, impotence and atrial fibrillation. He consumes 2-3 beers per week.He consumes 2-3 beers per week.
4. MRI to look for hepatic iron deposition 4. MRI to look for hepatic iron deposition
End of part 1End of part 1
Hx:Hx: 18 yo asymptomatic male referred for 6 mo hx of 18 yo asymptomatic male referred for 6 mo hx of abnl liver tests. Recent poor school performance and abnl liver tests. Recent poor school performance and diagnosis of ADD. No other medical problems.diagnosis of ADD. No other medical problems.Exam:Exam: mildly obese, no stigmata chronic liver disease. mildly obese, no stigmata chronic liver disease. Labs:Labs: AST 65, ALT 87, bili1.2, ALP 120. HBV and HCV AST 65, ALT 87, bili1.2, ALP 120. HBV and HCVserologies and autoantibodies neg. Ceruloplasmin 21.2 serologies and autoantibodies neg. Ceruloplasmin 21.2 (nl 22.9-43.1).(nl 22.9-43.1).Bx:Bx: mild steatosis with minimal inflammation and no mild steatosis with minimal inflammation and no fibrosis.fibrosis.What is the most appropriate next step?What is the most appropriate next step?
1. start ursodiol to treat NAFLD1. start ursodiol to treat NAFLD2. recommend an attempt at weight loss and 2. recommend an attempt at weight loss and repeat liver tests in 6 monthsrepeat liver tests in 6 months3. obtain a quantitative hepatic copper3. obtain a quantitative hepatic copper4. perform a copper stain on the liver biopsy4. perform a copper stain on the liver biopsy
WD OVERVIEWWD OVERVIEW
• Autosomal recessiveAutosomal recessive
–homozygote frequency 1:30,000homozygote frequency 1:30,000
–heterozygote frequency 1:100heterozygote frequency 1:100
• Impaired biliary excretion of copperImpaired biliary excretion of copper
• Excess copper deposits in the liver, Excess copper deposits in the liver, brain, cornea and other organsbrain, cornea and other organs
• Wilson’s should be considered in any patient < 30 years Wilson’s should be considered in any patient < 30 years of age with acute or chronic liver diseaseof age with acute or chronic liver disease
• Be highly suspicious of Wilson’s if:Be highly suspicious of Wilson’s if:
– liver disease with neurological or psychiatric disordersliver disease with neurological or psychiatric disorders
– acute liver disease with hemolytic anemiaacute liver disease with hemolytic anemia
• Diagnosis requires at least 2 of the following:Diagnosis requires at least 2 of the following:
• 32 yo male referred for abnormal liver tests32 yo male referred for abnormal liver tests• AST= 64, ALT= 85, Alk phos and bili normalAST= 64, ALT= 85, Alk phos and bili normal• He is healthy and asymptomaticHe is healthy and asymptomatic• PE- BMI= 28.4, no stigmata of CLDPE- BMI= 28.4, no stigmata of CLD• Ceruloplasmin 17.5 mg/dl (22.9-43.1)Ceruloplasmin 17.5 mg/dl (22.9-43.1)• Other tests for chronic liver disease negativeOther tests for chronic liver disease negative
What would you recommend?What would you recommend?
1. Liver biopsy1. Liver biopsy
2. Trial of weight loss and repeat liver tests2. Trial of weight loss and repeat liver tests
3. Slit lamp exam to look for KF rings3. Slit lamp exam to look for KF rings
Low index of suspicion High index of suspicionK F Rings
absent
Diagnosis Excluded
Liver Biopsy
24-hour urine CuNormal
Elevated
Quantitative Copper> 250 mg/g
Liver biopsycontraindicated
Genetic Testing
Modified from Handbook of Liver Disease 1998, Friedman and Keefe, eds.
WILSON DISEASEWILSON DISEASELIVER BIOPSYLIVER BIOPSY
• Necessary in most cases if no K-F rings or Necessary in most cases if no K-F rings or neurologic symptomsneurologic symptoms
• Histology is nondiagnostic (fat and Histology is nondiagnostic (fat and glycogenated nuclei)glycogenated nuclei)
• Quantitative copper is the gold standard for Quantitative copper is the gold standard for confirming the diagnosisconfirming the diagnosis
> 250 mcg/g dry weight diagnostic but not > 250 mcg/g dry weight diagnostic but not specificspecific
< 35 mcg/g dry weight excludes the diagnosis< 35 mcg/g dry weight excludes the diagnosis
WILSON DISEASE WILSON DISEASE GENEGENE
• ATP7B located on chromosome 13ATP7B located on chromosome 13
• Member of the cation-transporting P-type Member of the cation-transporting P-type ATPase subfamilyATPase subfamily
• > 200 mutations> 200 mutations
• Most patients with WD are compound Most patients with WD are compound heterozygotesheterozygotes
• Number of mutations makes gene less Number of mutations makes gene less useful for screeninguseful for screening
• 29 yo female referred for a family history of Wilson 29 yo female referred for a family history of Wilson diseasedisease
• Her brother was recently diagnosed with WDHer brother was recently diagnosed with WD• She is healthy and asymptomaticShe is healthy and asymptomatic• PE normalPE normal• Liver tests and ceruloplasmin normal Liver tests and ceruloplasmin normal • What would you recommend?What would you recommend?
1. Genetic testing for WD1. Genetic testing for WD
2. No additional evaluation2. No additional evaluation
3. Liver biopsy with quantitative copper3. Liver biopsy with quantitative copper
4. Slit lamp exam4. Slit lamp exam
5. Serum copper level5. Serum copper level
WILSON DISEASEWILSON DISEASEFAMILY SCREENINGFAMILY SCREENING
• Concentrate on siblings (25% risk)Concentrate on siblings (25% risk)
• Screening tests include liver tests, Screening tests include liver tests, ceruloplasmin, and slit lamp examceruloplasmin, and slit lamp exam
• Begin at age 5 and repeat every 5 Begin at age 5 and repeat every 5 years until age 20years until age 20
• Gene test if probands gene status is Gene test if probands gene status is known and other screening tests are known and other screening tests are equivocalequivocal
• 25 yo F referred for recently diagnosed WD25 yo F referred for recently diagnosed WD• Brother diagnosed with WD Brother diagnosed with WD • Ceruloplasmin 19.4 mg/dl (22.9-43.1)Ceruloplasmin 19.4 mg/dl (22.9-43.1)• Liver tests normal, genetic testing confirmed the diagnosisLiver tests normal, genetic testing confirmed the diagnosis• Healthy and asymptomaticHealthy and asymptomatic• PE- K-F rings otherwise normal examPE- K-F rings otherwise normal exam• She inquires about the need for treatmentShe inquires about the need for treatment• What would you recommend?What would you recommend?
1. Defer treatment until she becomes symptomatic1. Defer treatment until she becomes symptomatic
2. Liver biopsy and base treatment on hepatic copper 2. Liver biopsy and base treatment on hepatic copper levellevel
3. Begin treatment with Trientine3. Begin treatment with Trientine
4. Begin treatment with Zinc acetate4. Begin treatment with Zinc acetate
WILSON DISEASE WILSON DISEASE TREATMENTTREATMENT
• ““Decoppering” AgentsDecoppering” Agents
D-penicillamine D-penicillamine Start 250-500 mg/d and increase to 1-2 g/d qidStart 250-500 mg/d and increase to 1-2 g/d qid
limited role in carefully selectedlimited role in carefully selected
presymptomatic patientspresymptomatic patients
pregnant patients pregnant patients
patients on maintenance therapypatients on maintenance therapy• TetrathiomolybdateTetrathiomolybdate
copper chelatorcopper chelator
promising, not available in the USpromising, not available in the US
43 y.o. man being evaluated for lung tx for alpha-1-43 y.o. man being evaluated for lung tx for alpha-1-antitrypsin deficiency. Hx chronic liver test abnormalities. antitrypsin deficiency. Hx chronic liver test abnormalities. Drinks 6 beers/d. Used IV drugs 10 years ago. No Drinks 6 beers/d. Used IV drugs 10 years ago. No symptoms except for lung disease. Exam: normal except symptoms except for lung disease. Exam: normal except for lung exam.for lung exam.
Lab: ALP 1.5 X ULN, AST 34, ALT 27. Bilirubin, albumin, Lab: ALP 1.5 X ULN, AST 34, ALT 27. Bilirubin, albumin, INR, HBsAg, anti-HCV, iron studies, ceruloplasmin, and INR, HBsAg, anti-HCV, iron studies, ceruloplasmin, and ANA all nl. Bx: shown.ANA all nl. Bx: shown.
Which of the following is the most likely cause for the liver Which of the following is the most likely cause for the liver test abnormalities.test abnormalities.
• A1AT is serine protease which protects tissue A1AT is serine protease which protects tissue from proteasesfrom proteases
• Pi MM in 95% of the populationPi MM in 95% of the population
• Pi ZZ phenotype highest risk for liver diseasePi ZZ phenotype highest risk for liver disease
• Pi MZ phenotype may occasionally develop liver Pi MZ phenotype may occasionally develop liver disease, especially if another cofactor (viral, disease, especially if another cofactor (viral, NASH, EtOH)NASH, EtOH)
• Liver disease caused by abnormally folded Liver disease caused by abnormally folded protein accumulating in the ERprotein accumulating in the ER
ALPHA-1 ANTITRYPSIN DEFICIENCY ALPHA-1 ANTITRYPSIN DEFICIENCY Clinical FeaturesClinical Features
• Premature emphysema and liver diseasePremature emphysema and liver disease
• Neonatal hepatitis in 15-30% with Pi ZZ Neonatal hepatitis in 15-30% with Pi ZZ phenotypephenotype
• Chronic hepatitisChronic hepatitis
• Cirrhosis (most common metabolic Cirrhosis (most common metabolic indication for OLT)indication for OLT)
• Cirrhotics have a greatly increased risk of Cirrhotics have a greatly increased risk of HCCHCC
• No effective medical treatment of liver diseaseNo effective medical treatment of liver disease
• Avoid tobacco and alcoholAvoid tobacco and alcohol
• AIAT infusions useful in lung diseaseAIAT infusions useful in lung disease
• OLT is the only definitive treatment; curative OLT is the only definitive treatment; curative since the recipient assumes the Pi phenotype since the recipient assumes the Pi phenotype of the donorof the donor
• Protein expressed mainly on hepatocytesProtein expressed mainly on hepatocytes• Affinity for transferrin 30X less than TfR1Affinity for transferrin 30X less than TfR1• Classical HH phenotypeClassical HH phenotype
Kawabata et al. J Biol Chem 1999
JUVENILE HEMOCHROMATOSIS JUVENILE HEMOCHROMATOSIS
• First reported in 1932First reported in 1932
• A rare autosomal recessive disorder A rare autosomal recessive disorder characterized by:characterized by:
severe iron overload in early adulthoodsevere iron overload in early adulthood
cirrhosiscirrhosis
cardiomyopathy cardiomyopathy
hypogonadismhypogonadism
JH GENEJH GENE
• The gene was recently discoveredThe gene was recently discovered11
Located on chromosome 1Located on chromosome 1
Protein hemojuvelin; gene Protein hemojuvelin; gene HJVHJV
• 19 patients with JH from 12 families 19 patients with JH from 12 families
G320V mutation accounted for 2/3 of G320V mutation accounted for 2/3 of mutationsmutations
• Uncertain if mutations in HJV influence Uncertain if mutations in HJV influence disease progression in disease progression in HFE HFE HHHH